James R. Stuart, III

• $480 million merger acquisition of a NASDAQ-listed government IT contractor by a foreign NYSE-listed company.
• $440 million stock acquisition of a health management company by a NYSE-listed insurance company.
• $90 million stock acquisition of a technology-focused, defense and intelligence contractor.
• $165 million merger acquisition of a medical diagnostic company by a NASDAQ corporation.
• Joint venture establishing a high-volume specialty pharmacy business between two NYSE-listed corporations.
• $82 million merger acquisition of a defense and government services contractor.
• $70 million asset sale of a munitions and defense countermeasures manufacturing business.
• $40 million stock sale of a government training and simulations company to a NYSE corporation.
• Acquisition of a mail pharmacy business and related joint venture between two NYSE corporations.
• $50 million asset sale of telecommunications firm to a NYSE corporation.
• $20 million merger of a silicones manufacturer with a subsidiary of a NYSE corporation.
• $17 million tax-free stock-for-asset acquisition of a news database company to a NASDAQ corporation.
• $11 million asset sale by non-profit trade association in the health-care industry to NYSE corporation.
• $28 million merger acquisition of a software development business by a B2B e-commerce internet company.
• $24 million asset sale by non-profit trade association in the entertainment industry.
• $25 million stock acquisition and joint venture by a NYSE corporation with a foreign fruit distribution company.

In addition, Mr. Stuart's financing experience includes the following:

• $1.8 billion structured financing involving the liquidation of an international bank.
• $50 million revolving credit facility by a major U.S. bank to a publicly traded real estate investment trust.
• $38 million secured term and revolving loan facility by a major U.S. bank to a non-profit corporation.
• $100 million private placement of preferred stock by an undersea, fiber optics company.
• $14 million acquisition by publicly-traded, UK corporation of a minority interest in a medical device company.
• $15 million preferred stock private placement by a B2B e-commerce and software business.
• $7 million preferred stock private placement by an Israeli bio-tech company.
• $7 million common stock and convertible debt private placement by health insurance underwriter and reinsurance company.
• $10 million private placement by a high-speed cargo ship company to public and private investors.